FMT: Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis

Sponsor

Hamilton Health Sciences Corporation (Other)

Overall Status

Completed

CT.gov ID

NCT02606032

Collaborator

Hamilton Academic Health Sciences Organization (Other)

Enrollment

Location

Arms

56.9

Actual Duration (Months)

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The investigators will test the hypothesis that giving antibiotics prior to fecal transplant therapy for active UC increases the proportion of patients in remission at the end of treatment. The investigators will randomize patients aged 18 or over with active UC to antibiotics (metronidazole 500mg, doxycycline 100mg, Terbinafine 250 mg, all twice daily for two weeks); or identical placebo. At the end of two weeks the investigators will give all patients fecal transplant therapy twice per week for eight weeks from an anonymous donor stool.). Patients will complete a validated UC questionnaire, have a flexible sigmoidoscopy to assess the degree of inflammation in the colon and complete general and disease specific quality of life questionnaire as well as a questionnaire on anxiety and depression. Patients will complete the same questionnaires again at the end of treatment at week 9 when they will also have a repeat flexible sigmoidoscopy. The main outcome that will be assessed is the proportion of patients in remission from their UC at the end of treatment.

Condition or Disease	Intervention/Treatment	Phase
Ulcerative Colitis	Drug: Metronidazole Drug: Doxycycline Drug: Terbinafine Drug: Placebo	Phase 2

Detailed Description

Patients aged 18 or over with active UC defined as a Mayo score > 3 with an endoscopic score

0 will be eligible for the study. Subjects will be excluded if they are participating in another clinical trial, are unable to give informed consent, have severe comorbid medical illness, have concomitant Clostridium difficile infection or have severe UC requiring hospitalization. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNFα therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to randomization. Eligible patients will be randomized 1:1 to metronidazole 500mg bid, doxycycline 100mg bid, Terbinafine 250 mg and or identical placebos all for two weeks. Patients will all then receive their first FMT 1-3 days after completing their course of antibiotic/placebo. FMT will be administered twice per week for 8 weeks.

Eighty active UC patients will be randomized 1:1 according to a computer generated randomization list. Randomization will be administered centrally at the GI Clinical Trials Unit to ensure concealment of allocation.

Subjects will have a sigmoidoscopy (or colonoscopy if clinically indicated), physician assessment and complete a Mayo score, IBDQ questionnaire, EQ5D and HAD questionnaires at baseline. A repeat sigmoidoscopy, Mayo score, IBDQ, EQ5D and HAD questionnaires will be completed at 9 weeks, at exit from the study (one week after last FMT). No new medical therapies (e.g. corticosteroids, antibiotics, probiotics) will be permitted during the 9 week study period.

Study Design

Study Type:

Interventional

Actual Enrollment :

75 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Randomized Trial of Antimicrobials Versus Placebo in Addition to Fecal Microbiota Therapy in for the Induction of Remission in Active Ulcerative Colitis

Actual Study Start Date :

May 1, 2016

Actual Primary Completion Date :

Jan 1, 2021

Actual Study Completion Date :

Jan 27, 2021

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Metronidazole+doxycylcine+terbinafine Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days	Drug: Metronidazole active comparator Other Names: Flagyl Drug: Doxycycline active comparator Other Names: Vibramycin Drug: Terbinafine active comparator Other Names: Lamisil
Placebo Comparator: Placebo Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days	Drug: Placebo identical placebos to all antibiotics

Arm

Intervention/Treatment

Active Comparator: Metronidazole+doxycylcine+terbinafine

Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days

Drug: Metronidazole

active comparator

Other Names:

Flagyl

Drug: Doxycycline

active comparator

Other Names:

Vibramycin

Drug: Terbinafine

active comparator

Other Names:

Lamisil

Placebo Comparator: Placebo

Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days

Drug: Placebo

identical placebos to all antibiotics

Outcome Measures

Primary Outcome Measures

The primary outcome of the randomized trial is remission of UC defined as a Mayo score < 3 with an endoscopic Mayo score = 0 at the end of the trial Transplant Therapy in Ulcerative Colitis [9 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients aged 18 or over
Active UC defined as a Mayo score > 3
A Mayo endoscopic score > 0

Exclusion Criteria:

Participating in another clinical trial
Unable to give informed consent
Severe co-morbid medical illness
Concomitant Clostridium difficile infection
Severe UC requiring hospitalization.
Increase in medical therapy for UC in the last 12 weeks. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNF alpha therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will also be permitted provided the dose of steroid is not increased again. Stable intake of probiotic therapy also permitted.
Antibiotic therapy in the last 30 days.
Pregnant women.